Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMF-219 (Icovamenib) in Advanced Liquid Malignancies
NCT05153330Phase 1Terminated
- Sponsor
- Biomea Fusion
- Start
- Jan 2022
- Primary completion
- Feb 2025
- Modality
- Covalent Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of icovamenib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia (MPAL) and 4 more (2 arms), sponsored by Biomea Fusion. Primary endpoint: Optimal Biologic Dose and Recommended Phase 2 Dose. Started Jan 2022; status: terminated.
02
Drugs
icovamenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)diffuse large B-cell lymphoma (DLBCL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05153330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153330.